M2Bio creates innovative healthcare solutions for various disorders and mental illnesses such as seizure, depression, disorder, anxiety, pneumonia, dystonia, Crohn’s disease, Parkinson’s disease, and many other such conditions through cannabis and mushroom-based science backed by solid scientific research with drug target discovery, clinical and per-clinal trials and FDA approval.
The research team at M2Bio are currently exploring the anti-inflammatory properties of psilocybin with in vitro studies.
M2Bio is owned and operated by Wuhan General Group Inc.
M2Bio
The company’s mission is to be a global leader in the psilocybin medical health sector and bring botanical-based medicine to the forefront with best-practice science and medicine, clinical research and emerging new technologies.
“We design our CBD & Mushroom products to improve the lives of all our consumers.”
Activities
B2B
B2C
Biotech
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates